Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Weight loss drugs like semaglutide could add £4.5 billion to the UK economy annually, boosting productivity and reducing ...

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...